Project Details


The prognosis for patients with relapsed/refractory acute myeloid leukemia (AML) is very poor and it is therefore essential to develop new therapeutic options for this malignancy. It is clear that the immune system plays a crucial role in combatting leukemic cells, however, to date no immunotherapeutics have proven successful in the clinic. Natural killer cells are one population of immune cells which have been shown to be important for targeting leukemic cells. Leukemic cells have a mechanism, however, to evade natural killer cells. We are proposing to test a potential therapeutic, the 7C6 antibody, that has the potential to allow for the leukemic cells to be better recognized by natural killer cells. We will test this antibody alone and in combination with drugs that increase the expression of proteins on the surface of leukemia cells which are recognized by NK cells. The studies will be performed on leukemic cells from patients with AML and on mice who have been injected with human leukemic cells. Ultimately, results from this work could serve as preclinical rationale for a clinical trial of this novel therapeutic in AML patients.
Effective start/end date1/01/2031/12/21


  • Leukemia Research Foundation: $100,000.00


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.